前列舒通联合盐酸坦索罗辛治疗慢性前列腺炎疗效评价及对血清PSA、NGF、TGF-β的影响

Study on Effectof Alprostol Combined with Tamsulosin Hydrochloride in Treatmento Chronic Prostatitis and Its Effect on PSA, NGF and TGF-β in Serum

目的:探讨前列舒通联合盐酸坦索罗辛治疗慢性前列腺炎的治疗效果。方法:以100例慢性前列腺炎患者作为研究对象,回顾性分析其临床病例资料,将其分为观察组(52例)与对照组(48例)。其中对照组患者使用盐酸坦索罗辛进行治疗,而观察组患者联合使用前列舒通与盐酸坦索罗辛进行治疗。观察并比较两组患者的治疗效果。结果:(1)治疗前,两组患者NIH-CPSI、VAS、PPI评分差异不显著(P>0.05)。治疗后,观察组患者上述指标值明显低于对照组(P<0.05)。(2)治疗前,两组患者前列腺液炎性因子水平(IL-2、IL-6、IL-8、TNF-α)差异不显著(P>0.05)。治疗后相比较对照组,观察组患者上述指标值明显更低(P<0.05);(3)治疗前,两组患者血清中CD3^+、CD4^+、CD8^+、CD4^+/CD8^+等T淋巴细胞亚群差异不显著(P>0.05)。治疗后相比较对照组,观察组患者T淋巴细胞亚群水平更优(P<0.05);(4)治疗前,两组患者尿动力学指标水平(MFR、AFR、排尿量)差异不显著(P>0.05)。治疗后,观察组患者上述指标值明显高于对照组(P<0.05);(5)治疗前,两组患者SlgA、白细胞及CTGF水平差异不显著(P>0.05)。治疗后,观察组患者上述指标值明显低于对照组(P<0.05);(6)治疗前,两组患者血清PSA、NGF、TGF-β水平差异不显著(P>0.05)。治疗后,观察组患者上述指标值明显低于对照组(P<0.05);(7)观察组患者临床治疗有效率明显高于对照组(92.31%VS 72.92%,P<0.05)。结论:前列舒通联合盐酸坦索罗辛治疗慢性前列腺炎,能明显减轻患者疼痛,降低机体炎性反应与血清PSA、NGF、TGF-β水平,改善其免疫功能,治疗效果显著。因此,该方法值得在临床上推广与应用。

Objective: To study the effect of alprostol combined with tamsulosin hydrochloride in the treatment process of chronic prostatitis. Methods: A total of 100 patients with chronic prostatitis were considered as study objects and the clinical data was analyzed retrospectively. They were divided into observation group(n=52) and control group(n=48). The patients were treated with alprostol combined with tamsulosin hydrochloride in the observation group, while those in the control groupwere treated with tamsulosin hydrochloride. The treatment effects were observed and compared. Results:(1)Before treatment, there was no obvious difference about scores of NIH-CPSI, VAS or PPI between these two groups(P>0.05). After treatment, the indexes were significantly lower in observation group compared with those in the control group(P<0.05).(2)There was no significant difference in the level of prostatic fluid inflammatory factors(IL-2, IL-6, IL-8, TNF-α) between the two groups before treatment(P>0.05). Compared with the control group, the above indexes values in the observation group were significantly lower than those in the control group(P<0.05).(3)Before treatment, there was no significant difference in T lymphocyte subsets such as CD3^+, CD4^+, CD8^+ or CD4^+/CD8^++ between the two groups(P>0.05). Compared with the control group, the T lymphocyte subsets in the observation group were better than those in the control group(P<0.05).(4)Before treatment, there was no significant difference in the level of urodynamic indexes(MFR, AFR, urine volume) between the two groups(P>0.05). After treatment, the above indexes values in the observation group were significantly higher than those in the control group(P<0.05).(5)Before treatment, the levels of SlgA, leukocyte and CTGF were not significantly different between the two groups(P>0.05). After treatment, the above indexes in the observation group were significantly lower than those in the control group(P<0.05).(6)Before treatment, there was no significant difference in serum PSA, NGF or TGF-β levels between the two groups(P>0.05). After treatment, the above indexes values in the observation group were significantly lower than those in the control group(P<0.05).(7)The effective rate in the observation group was significantly higher than that of the control group(92.31% vs 72.92%, P<0.05). Conclusion: Alprostol combined with tamsulosin hydrochloride in the treatment process of chronic prostatitis can obviously alleviate the pain of patients and reduce the inflammatory reaction of the body and the serum levels of PSA, NGF and TGF-β, with improving the immune function of patients. The treatment effect is remarkable. Therefore, this method is worthy of popularizing and using in clinic.